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Coxibs and Heart Disease
What We Have Learned and What Else We Need to Know
Ignatius Gerardo E. Zarraga, MD,* Ernst R. Schwarz, MD, PHD, FACC*†
Galveston, Texas; and Los Angeles, California
Since their approval in 1998, the popularity of selective cyclooxygenase-2 (COX2) inhibitors has swung from a
domination of drug sales to serious disputes about their cardiovascular safety. Despite the numerous studies on
COX2 inhibitors that have emerged, drawing conclusions about their cardiovascular safety has been complicated
by conflicting results, underpowered clinical trials, and the lack of a placebo group and use of post hoc analyses
in many trials. Nonetheless, certain conclusions can be made with reasonable accuracy. This review addresses
the controversy in 3 segments. It begins with a discussion of the several mechanisms proposed to explain how selec-
tive COX2 inhibition impacts the cardiovascular system. This is followed by a recount of the several clinical studies
that delved into the cardiovascular outcomes associated with COX2 inhibitors. Finally, answers to key questions are
provided to assist the clinician in devising a systematic approach to the risk-benefit analysis of COX2 inhibitors in ac-
tual practice. (J Am Coll Cardiol 2007;49:1–14) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.003t
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rhe transformation of arachidonic acid to prostaglandin H2
PGH2) is a step that commits arachidonic acid down the
ath of prostaglandin-thromboxane synthesis. This trans-
ormation is catalyzed by cytosolic prostaglandin G/H
ynthase, more commonly known as cyclooxygenase
COX). Prostaglandin H2 is an unstable intermediate and is
urther converted to one of many prostanoids, such as
rostacyclin (PGI2) and thromboxane A2 (TXA2), by
issue-specific isomerases. As early as 1987, evidence
merged showing that the COX enzyme probably existed in
isoforms (1). Today it is well established that these
soforms, COX1 and COX2, exist and are encoded by
eparate genes on different chromosomes.
Cyclooxygenase inhibition formed the basis for the suc-
ess of non-steroidal anti-inflammatory drugs (NSAIDs) in
reating a variety of pain syndromes. The drawback, how-
ver, was that every year, 2% to 4% of patients taking
SAIDs suffered from symptomatic gastrointestinal ulcers
nd their complications (2). As the science behind the COX
nzyme progressed, it became apparent that COX2 inhibi-
ion mediated the anti-inflammatory effects of NSAIDs,
hereas COX1 inhibition was responsible for the adverse
ffects on the gastrointestinal tract. It therefore became
easonable to assume that inhibiting COX2 selectively
ould result in the same anti-inflammatory benefits that
onselective NSAIDs provided but with fewer gastrointes-
rom the *Division of Cardiology, Department of Internal Medicine, The University
f Texas Medical Branch, Galveston, Texas; and the †Division of Cardiology,
epartment of Internal Medicine, Cedars-Sinai Medical Center and University of
alifornia Los Angeles, Los Angeles, California.d
Manuscript received June 27, 2006; revised manuscript received July 31, 2006,
ccepted August 8, 2006.inal side effects. This rekindled the interest of pharmaceu-
ical industries in manufacturing new analgesic and anti-
nflammatory medications known as selective COX2
nhibitors or coxibs. In 1995, the first generation of coxibs,
elecoxib (by Monsanto) and rofecoxib (by Merck), entered
linical trials. In 1998, celecoxib was approved by the U.S.
ood and Drug Administration (FDA), followed by rofe-
oxib in 1999. These drugs soon dominated the
rescription-drug market for NSAIDs. By October 2000,
elecoxib and rofecoxib had sales exceeding $3 billion in the
.S. (3).
At the time that COX2 inhibitors were approved, ran-
omized trials aimed at proving their gastrointestinal safety
ere still ongoing. It was not until 2000 that 2 large studies,
LASS (Celecoxib Long-Term Arthritis Safety Study) (2)
nd VIGOR (Vioxx Gastrointestinal Outcomes Research)
4), showed their superior gastrointestinal profile over con-
entional NSAIDs. Both studies, however, were not free of
ontroversy. For the CLASS trial, the gastrointestinal
uperiority of celecoxib in its 6-month data became disput-
ble when this superiority failed to manifest in its 12-month
ata (5). On the other hand, the VIGOR study raised
oncerns about the cardiovascular safety of rofecoxib. To
mplify this concern, near the time of completion of the
IGOR study, preliminary evidence supporting the biologic
lausibility of COX2-induced adverse cardiovascular events
merged. From hereon, the use of coxibs became plagued by
afety concerns on the basis of both mechanistic and clinical
ata.
As a result of the evolving understanding of the potential
isks of selective COX2 inhibition, in 1999, Merck intro-
uced a standard operating procedure to evaluate and
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in all ongoing and future rofe-
coxib clinical trials (6). In 2002,
the FDA also issued a new warn-
ing in the package insert of rofe-
coxib, stating that “. . . caution
should be exercised when Vioxx
is used in patients with a medical
history of ischemic heart dis-
ease.” This decision of the FDA
to opt for a mere label change and
not a more practice-changing in-
tervention, such as compelling
manufacturers to initiate trials on
cardiovascular safety, has been
highly criticized (7). As a matter
of fact, for a good number of
years after the VIGOR trial
stirred controversy, no random-
ized controlled trial was initiated
to address the cardiovascular tox-
icity of coxibs as a primary end
point. Instead, more trials were
esigned to show the efficacy of coxibs for other indications,
uch as the prevention of recurrent colonic polyps, manage-
ent of postoperative pain, and slowing down of the
rogression of Alzheimer’s dementia. One such trial was the
PPROVe (Adenomatous Polyp Prevention on Vioxx)
tudy (8), which now stands among landmark clinical trials.
t was prematurely terminated after investigators found an
ncreased cardiovascular risk among patients taking rofe-
oxib, and served as the basis for the immediate worldwide
ithdrawal of rofecoxib by Merck on September 30, 2004.
housands of lawsuits against Merck followed this event,
ecause by this time an estimated 80 million people had
lready taken the drug (9).
Not too long thereafter, the results of 2 more randomized
rials of coxibs were published and showed unfavorable
ardiovascular outcomes as well. One was a celecoxib trial
or colonic adenoma prevention (10), and the other was a
aldecoxib/parecoxib trial for the management of postoper-
tive pain after coronary artery bypass grafting (CABG)
11). In addition to being linked with a heightened cardio-
ascular risk, valdecoxib and parecoxib had previously been
mplicated in life-threatening hypersensitivity reactions, in-
luding anaphylaxis, angioedema, Stevens-Johnson syn-
rome, and toxic epidermal necrolysis (12). Consequently,
n April 7, 2005, the FDA requested that Pfizer remove
aldecoxib from the market. Furthermore, the FDA issued
cautionary note against the coxibs, and NSAIDs in
eneral: “. . . an increased risk of serious adverse [cardiovas-
ular] events appears to be a class effect of NSAIDs
excluding aspirin). The FDA has requested that the pack-
ge insert for all NSAIDs, including Celebrex, be revised to
nclude a boxed warning to highlight the potential increased
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CHF  congestive heart
failure
COX  cyclooxygenase
FDA  Food and Drug
Administration
HR  hazard ratio
MI  myocardial infarction
NSAID  non-steroidal anti-
inflammatory drug
OA  osteoarthritis
PG  prostaglandin
PPI  proton pump
inhibitor
RA  rheumatoid arthritis
TX  thromboxaneisk of [cardiovascular] events and . . . to include a contra- undication for use in patients immediately postoperative
rom CABG” (13).
In the following discussion, we highlight the several
echanisms that have emerged to explain how selective
OX2 inhibition impacts the cardiovascular system. We
hen review the landmark clinical studies that delved into
he cardiovascular outcomes associated with coxibs. Finally,
e present a systematic approach to the risk-benefit analysis
f coxibs in actual clinical practice.
echanisms Underlying
he Cardiovascular Effects
f Selective COX2 Inhibitors
yclooxygenase-1 is expressed constitutively in most cell
ypes and is the only functioning COX in mature platelets.
yclooxygenase-2, on the other hand, is an isoform with an
xpression that is induced by inflammatory stimuli such as
acterial endotoxin and cytokines. Induction of COX2
xpression has also been demonstrated in atheromatous
laques (14,15) and neoplasms (16). This led to the hypoth-
sis that COX2 inhibition might be useful in the treatment
r prevention of atherosclerosis and various cancers. In fact,
few reports have suggested that COX2 inhibition might
e cardioprotective. For example, Dinchuk et al. (17) have
hown that COX2-knockout mice developed cardiac fibro-
is. Two histologic studies, performed by Baker et al. (14)
nd Schonbeck et al. (15), showed the presence of COX2 in
therosclerotic lesions of native and transplanted coronary
rteries, but not in normal coronary arteries. Furthermore,
OX2 expression was localized to macrophages/foam cells,
edial smooth muscle cells, and endothelial cells within the
therosclerotic plaque, all of which are established key
layers in atherogenesis. A similar study by Cipollone et al.
18) on carotid plaques showed a significantly higher con-
entration of COX2 in plaques associated with a recent
ransient ischemic attack or stroke compared with asymp-
omatic plaques. Cyclooxygenase 2 expression also appears
o be induced by many of the same stimuli implicated in the
evelopment of atherosclerosis, including free radicals (19),
umor necrosis factor, interleukin-1 (20), platelet-derived
rowth factor (21), and increased arterial wall shear stress
22). Finally, because inflammation of the endothelium is
nown to diminish its capacity to produce nitric oxide, it has
een suggested that COX2 inhibition can improve endo-
helial function in this setting. This was shown by 2 small,
hort-term studies (2 weeks in duration) in which cele-
oxib led to significant improvements in flow-mediated
asodilation compared with placebo in patients with hyper-
ension or coronary artery disease (CAD) (23,24).
In reality, predicting the effect of COX2 inhibition on the
ardiovascular system has not been straightforward. Al-
hough COX2 can be viewed as a “bad” player in the
therosclerotic process based on most of the aforementioned
ata, it can also be regarded as a “good” player if its
p-regulation is thought of as a compensatory mechanism
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January 2/9, 2007:1–14 Coxibs and Heart Diseaseo help maintain vascular health. In addition, in 1998, it
ecame apparent that the 2 COX isoforms affected the
alance of vasoactive prostanoids differently. Several studies
uggested that TXA2, a vasoconstrictor and promoter of
latelet aggregation, was largely COX1-derived, whereas
he synthesis of the vasodilator and potent inhibitor of
latelet aggregation, PGI2, was linked to COX2 induction
25,26). Specifically, the up-regulation of COX2 (e.g., by
nterleukin-1) shifted arachidonic acid metabolism from
XA2 synthesis to the preferential production of PGI2
27). Furthermore, although nonselective COX inhibitors,
uch as aspirin and ibuprofen, suppressed TXA2 production
n platelets, selective COX2 inhibitors did not (25,26).
ltogether, a clear suggestion was made that COX2 inhi-
ition could tip the vascular homeostasis into a prothrom-
otic state.
More investigations have since led to the unraveling of
ther mechanisms behind coxib-induced cardiovascular
arm. For example, it has been suggested in animal models
hat COX2 mediates the cardioprotective effects of the late
hase of ischemic preconditioning and that PGE2 and
GI2 are the likely effectors of such protection (28,29).
ccordingly, COX2 inhibition can block the protective
ffect of late-phase preconditioning against myocardial
tunning and infarction. In another study of mice models of
therosclerosis, antagonism of the TXA2 receptor was
hown to retard atherogenesis, but the combination of
elective COX2 inhibition and TXA2-receptor antagonism
esulted in atherosclerotic lesions that lacked fibrotic caps,
uggesting a destabilizing effect on these plaques (30). Wu
t al. (31) also showed that when angiogenesis was induced
y vascular endothelial growth factor, cell proliferation and
he formation of vascular structures were increased in
uman umbilical vein endothelial cells that overexpressed
OX2, whereas cell proliferation was significantly reduced
hen the endothelial cells were pretreated with a selective
OX2 inhibitor. These findings suggest that COX2 may be
ardioprotective, in part because of its role in angiogenesis.
s will be discussed in later sections of this review, some
OX2 inhibitors have been associated with hypertension
nd oxidative modification of lipids, providing yet another
echanism by which these drugs might produce adverse
utcomes.
isk of Ischemic
ardiovascular Events With Rofecoxib
he first major postmarketing multicenter trials on COX2
nhibitors were the CLASS and VIGOR trials (Tables 1
nd 2) (2,4). Although safety concerns were raised by the
IGOR trial, neither of these trials convinced the entire
edical community of the increased cardiovascular risk of
oxib use. The CLASS trial was a double-blind trial of
,968 patients with osteoarthritis (OA) or rheumatoid
rthritis (RA) who were randomized to high-dose celecoxib,
buprofen, or diclofenac. Patients were allowed to take gardioprotective doses of aspirin. At the end of 6 months,
here was no difference in the incidence of cardiovascular
vents between the celecoxib and nonselective NSAID
roups, irrespective of aspirin use. The VIGOR study was a
imilar trial that randomized 8,076 patients with RA to
ither 50 mg rofecoxib daily or 500 mg naproxen twice
aily. As in the CLASS trial, the coxib dose was over the
aximum recommended dose for long-term administra-
ion, and was in keeping with the objective of the study,
hich was to rigorously assess the gastrointestinal safety of
he drug even at supratherapeutic doses. Unlike the CLASS
rial, patients in the VIGOR trial were prohibited from
sing aspirin. During a median follow-up of 9 months, the
ncidence of myocardial infarction (MI) was several-fold
igher in the rofecoxib group: 4-fold higher as reported by
he VIGOR study group; 5-fold higher as reported in the
DA files (32). Because the study lacked a placebo arm, it
as unclear how much of the increased risk of MI was
ttributable to a harmful effect of high-dose rofecoxib, a
rotective effect of naproxen, chance (because of the small
umber of events), or a combination of these factors.
When this unexpected outcome from rofecoxib unfolded
nd mechanisms to explain its biologic plausibility emerged,
everal observational studies were published to help confirm
he finding, but the results were conflicting (33–35). Pooled
nalyses of previous randomized trials likewise did not
rovide a clear answer to the issue. Three pooled analyses of
rials before and after the marketing of rofecoxib, published
rom 2001 to 2003, supported the cardiovascular safety of
ofecoxib (Table 1). These included the studies by Konstam
t al. (6) and Reicin et al. (36), which found similar rates of
hrombotic events and similar rates of the APTC (Anti-
latelet Trialists’ Collaboration) end point (combined inci-
ence of death from cardiovascular, hemorrhagic, or un-
nown cause; nonfatal MI; and nonfatal stroke) with
ofecoxib, placebo, and comparator non-naproxen NSAIDs.
he data evaluated by Konstam et al. (6) included the
esults of the VIGOR trial and indicated that naproxen was
n outlier NSAID in that it was associated with a lower risk
f cardiovascular events compared with rofecoxib. In an
pdated review, Weir et al. (37) reiterated in 2003 that
ofecoxib was safe from a cardiovascular standpoint. In
ddition to the pooled analyses of Konstam et al. (6) and
eicin et al. (36), they included data from the Alzheimer’s
isease and Mild Cognitive Impairment program, a com-
osite of placebo-controlled trials that again showed similar
ates of cardiovascular events in the rofecoxib and placebo
roups.
In contrast to the above data, in 2001, Mukherjee et al.
38) published a review highlighting the cardiovascular risk
ssociated with coxibs. In their analysis of the VIGOR
tudy, the relative risk of an adjudicated cardiovascular
hrombotic event with rofecoxib compared with naproxen
as 2.38 (95% confidence interval [CI] 1.39 to 4.00). They
hen looked into the rate of similar events in a placebo
roup, which they derived from a meta-analysis of 4 aspirin
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January 2/9, 2007:1–14 Coxibs and Heart Diseaserimary prevention trials. Compared with this placebo
roup’s annualized MI rate of 0.52%, the corresponding
ates were higher in the rofecoxib group of the VIGOR trial
0.74%, p  0.004) and the celecoxib group of the CLASS
rial (0.80%, p  0.02). This analysis, however, was criti-
ized for comparing patients without rheumatoid arthritis
placebo group) with the patients of the VIGOR trial, all of
hom had RA and were potentially at an increased risk for
ardiovascular events (39).
After rofecoxib was withdrawn from the market based on
he results of the APPROVe study, Jüni et al. (40) came out
ith a meta-analysis of 18 randomized controlled trials that
ompared rofecoxib with nonselective NSAIDs or placebo
n patients with chronic musculoskeletal disorders (Table 1).
fter analyzing a total of 64 MI events in 21,432 patients,
he relative risk of MI with rofecoxib vs. control was 2.24
95% CI 1.24 to 4.02). Using cumulative meta-analysis, the
nvestigators showed that this significantly increased risk
hould have become evident as early as 2000. Although
stimates of the relative risk varied depending on whether
ofecoxib was compared with placebo, a non-naproxen
SAID, or naproxen in the various trials, a test of interac-
ion was not significant and it was concluded that the type
f control had no important impact on the relative risk.
nterestingly, the investigators showed that the only source
f variation in risk of MI related to whether or not adverse
vents were examined by an external end point committee.
n this light, they warned that data on adverse events from
ndustry-sponsored randomized trials were trustworthy only
f an independent end point committee was involved (41).
o address the question of cardioprotection from naproxen,
he investigators analyzed 11 observational studies that
ompared the cardiovascular risk of naproxen use with that
f no NSAID use or use of a non-naproxen NSAID. The
ombined estimate of the relative risk of MI with naproxen use
as 0.86 (95% CI 0.75 to 0.99). It therefore seemed that
aproxen had only a small, if any, cardioprotective effect, and
his effect alone could not have accounted for the higher MI
ates in the rofecoxib arm of trials such as the VIGOR trial.
The verdict on the rofecoxib controversy was finally laid
own by Merck when the results of the APPROVe trial
ame out (Table 1) (8). This trial was designed to test the
ypothesis that 3 years of rofecoxib treatment will reduce
he risk of recurrent adenomatous polyps in patients with a
istory of colorectal adenomas. At least 1,000 patients were
andomized to 1 of 2 arms, 25 mg rofecoxib daily or
lacebo, and approximately 28% of the patients were des-
gnated as having a high cardiovascular risk profile. Patients
ere allowed to take low-dose aspirin for cardiovascular
rotection, although only about 20% actually took aspirin at
ome point in the study. On September 30, 2004, about 2
onths before its planned completion date, the study was
erminated after an interim review of the external safety
onitoring board found a higher risk of thrombotic events,
ainly MI and stroke, in the rofecoxib arm. Among thosewho took rofecoxib, this risk was especially high in thoseT A S 2
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Coxibs and Heart Disease January 2/9, 2007:1–14ho had a history of symptomatic atherosclerotic cardio-
ascular disease or diabetes. Although the original article
uggested that the excess risk surfaced only after 18 months
f rofecoxib use, a correction to this claim was recently
ade; a re-analysis of the data did not suggest that a shorter
ourse (18 months) of rofecoxib was safe (42). Although
he APPROVe trial was a relatively small trial that was not
esigned primarily to investigate cardiovascular outcomes, it
rought forward a new dimension to the rofecoxib analysis
y using placebo as the control and having a treatment and
ollow-up duration well beyond 24 months. Thereafter
erck could have accepted a black box warning, but it chose
o pull the drug out of the world market immediately.
On May 11, 2006, Merck released their data on an
ff-drug extension of the APPROVe trial in which they
ollowed up the over 2,500 patients for another year after
iscontinuation of the study drug (43). There continued to
e more cardiovascular thrombotic events in those previ-
usly randomized to rofecoxib (28 events vs. 16 events in
hose previously randomized to placebo), with a relative risk
f 1.64 (95% CI 0.89 to 3.04). When the off-drug extension
ata were combined with the 3-year on-drug data, the
elative risk over 4 years was 1.74 (95% CI 1.19 to 2.55),
inting that the increased cardiovascular risk in those who
ook rofecoxib was slow to abate—in fact, more slowly than
xpected if the only mechanism invoked was a coxib-
nduced prothrombotic state. An in-depth analysis of the
ff-drug extension data is currently under way. In the
eantime, continued follow-up of this cohort of patients
ill be valuable in understanding the long-term risks asso-
iated with rofecoxib.
isk of Ischemic Cardiovascular
vents With the Other Coxibs
hether or not the cardiovascular risks of rofecoxib is a
lass effect of COX2 inhibitors is an issue that needs
larification. After all, the various COX2 inhibitors have
mportant structural, pharmacodynamic, and pharmacoki-
etic differences, as listed in Table 3 (44). Celecoxib, for
xample, is the least selective of the coxibs; with a COX1:
OX2 half-maximal inhibitory concentration ratio of 30, it
s only slightly more COX2-selective than diclofenac, which
tructures, Pharmacodynamics, and Pharmokinetics of the Various
Table 3 Structures, Pharmacodynamics, and Pharmokinetics o
Structure
COX1:COX2
IC50* Ratio
First-generation coxibs
Celecoxib Sulfonamide 30
Rofecoxib Sulfonyl 276
Second-generation coxibs
Valdecoxib Sulfonamide 261
Etoricoxib Sulfonyl 344
Lumiracoxib Phenyl acetic acid 433dapted and reprinted, with permission, from Fitzgerald et al. (44). *IC50 represents the concentration o
COX  cyclooxygenase.as a ratio of 20. In terms of metabolism, rofecoxib is the
nly one that it is inactivated by cytosolic reductases. The
ther coxibs are oxidized by cytochrome P450 enzymes,
aking them potentially more susceptible to drug-drug
nteractions. Furthermore, an in vitro study by Walter et al.
45) suggested that coxibs with a sulfone moiety, namely
ofecoxib and etoricoxib, enhanced the susceptibility of
ipids to oxidative modification through a process unrelated
o their COX activity. This pro-oxidant property was not
bserved with other coxibs and nonselective NSAIDs.
nherent differences like these can potentially translate into
ifferences in in vivo behaviors and clinical outcomes.
In fact, a few observational studies have suggested differ-
nces in cardiovascular risk between rofecoxib and celecoxib.
n a case-control study by Kimmel et al. (46), the adjusted
dds ratios for MI among celecoxib users and rofecoxib
sers compared with individuals who did not use NSAIDs
ere 0.43 (95% CI 0.23 to 0.79) and 1.16 (95% CI 0.70 to
.93), respectively. In another case-control study using data
rom Kaiser Permanente, Graham et al. (47) showed that
he odds ratio for an acute MI and sudden cardiac death
mong rofecoxib users compared with celecoxib users was
.47 (95% CI 0.99 to 2.17) if the dose was25 mg/day and
.58 (95% CI 1.27 to 10.11) if the dose was 25 mg/day.
inally, in a study by Solomon et al. (48) that compared the
ates of MI and ischemic stroke in users of nonselective
SAIDs or coxibs (including celecoxib, rofecoxib, and
aldecoxib) with those in nonusers, rofecoxib was the only
oxib that significantly increased the risk of cardiovascular
vents. Taken together, these studies suggested that the
ncreased cardiovascular risk seen with COX2 inhibitors was
ost prominent with, and perhaps limited to, rofecoxib.
On the other hand, some randomized trials only
trengthened the notion that adverse cardiovascular events
ere a class effect of COX2 inhibitors. The APC (Adenoma
revention with Celecoxib) study was one such trial (10)
Table 2). It randomized 2,035 patients with a history of
olorectal neoplasia to receive placebo or celecoxib, either
00 or 800 mg/day. During 3 years of follow-up, celecoxib
as associated with a dose-related increase in the composite
nd point of cardiovascular death, nonfatal MI, stroke, and
eart failure, and this effect was independent of concomitant
ctive COX2 Inhibitors
Various Selective COX2 Inhibitors
Oral Bioavailability (%) Half-Life (h) Metabolism
22–40 2–4 Cytochrome P450
92–93 2–3 Cytosolic reduction
83 2.3 Cytochrome P450
100 1 Cytochrome P450
74 2–3 Cytochrome P450Sele
f thef the drug required to inhibit 50% of enzyme activity.
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January 2/9, 2007:1–14 Coxibs and Heart Diseasese of aspirin or lipid-lowering medication. Notably, these
ndings contrasted with those of other studies, including
LASS (celecoxib vs. ibuprofen or diclofenac) and 3 un-
ublished studies, namely PreSAP (Prevention of Colorec-
al Sporadic Adenomatous Polyps; celecoxib vs. placebo),
DAPT (Alzheimer’s Disease Anti-inflammatory Preven-
ion Trial; celecoxib vs. naproxen or placebo), and
UCCESS-1 (the first Successive Celecoxib Efficacy and
afety Study; celecoxib vs. naproxen or diclofenac), all of
hich did not show any statistical difference in the risk of
ardiovascular thrombotic events between celecoxib and a
omparator nonselective NSAID and/or placebo (49) (Ta-
le 2). It should be emphasized, however, that like the
PPROVe study, the strength of the APC trial lay in its use
f a placebo as control and its treatment and follow-up
uration of over 24 months. In a recent meta-analysis of
andomized trials of celecoxib, Caldwell et al. (50) con-
luded that celecoxib significantly increased the risk of MI
hen compared with placebo (odds ratio 2.26, 95% CI 1.0
o 5.1) or when compared with placebo, diclofenac, ibupro-
en, and paracetamol (odds ratio 1.88, 95% CI 1.15 to 3.08),
ut did not significantly increase the risk of other outcomes
uch as cardiovascular death and stroke.
Analogous to the results of the APPROVe and APC
tudies, 2 trials of valdecoxib and its pro-drug, parecoxib, for
ain management after elective CABG questioned the
afety of these drugs in high-risk patients (11,51) (Table 4).
he larger of the 2 studies randomized 1,671 patients to one
f three 10-day treatment arms: 1) intravenous parecoxib
ollowed by oral valdecoxib; 2) intravenous placebo followed
y oral valdecoxib; or 3) placebo. All patients received
ow-dose aspirin and were allowed to receive opiates post-
peratively as needed. During only 30 days of follow-up,
ardiovascular events, including MI, cardiac arrest, stroke,
ardiovascular Safety Data for Parecoxib/Valdecoxib From Random
Table 4 Cardiovascular Safety Data for Parecoxib/Valdecoxib F
Trial
Number
of Patients
Patient
Characteristics Interven
CABG surgery trial
by Ott et al. (51)
462 Postelective CABG Parecoxib 40 m
followed by v
40 mg PO q1
IV/PO placeb
CABG surgery trial
by Nussmeier
et al. (11)
1,671 Postelective CABG Parecoxib 40 m
then 20 mg
followed by v
20 mg PO q1
placebo follo
valdecoxib 2
q12 h vs. IV/
placebo (ASA
all patients p
ABG  coronary artery bypass grafting; DVT  deep venous thrombosis; IV  intravenous; PO 
and 2.nd pulmonary embolism, occurred more frequently in tatients who received parecoxib and valdecoxib than in
hose who received placebo (2.0% vs. 0.5%, p  0.03).
Lumiracoxib was evaluated in the TARGET (Therapeu-
ic Arthritis Research and Gastrointestinal Event Trial)
tudy (52) (Table 5). This was the first published study of
oxibs in arthritis patients that prospectively evaluated
redefined cardiovascular events along with gastrointestinal
vents. Over 18,000 patients were randomized to lumira-
oxib (at doses 2 to 4 times higher than the recommended
ose for OA), naproxen, or ibuprofen. Patients who were
eemed high-risk for cardiovascular disease were started on
ow-dose aspirin before enrollment. After 1 year, the inci-
ence of the APTC end point was slightly, but not
ignificantly, higher in the lumiracoxib group compared
ith the nonselective NSAID group; this lack of statistical
ifference was not influenced by the use or nonuse of
spirin. Similarly, for MIs, no significant difference was
ound between lumiracoxib users and the combined nonse-
ective NSAID group; however, there was an excess of
vents in the lumiracoxib arm, which became more prom-
nent when naproxen was used as the comparator. Three
oints about this trial deserve mention. First, although it
as a large trial, it was still insufficiently powered to detect
ignificant differences in MI among non-aspirin users.
econd, patients on low-dose aspirin had at least a 2-fold
igher number of composite vascular events than did non–
spirin-treated patients, whether they were assigned to
umiracoxib or to nonselective NSAIDs. Counterintuitive as
t may seem, this could reflect either an inability of aspirin
o provide cardioprotection against lumiracoxib and
SAIDs, or the potentially higher baseline risk of those
eing treated with aspirin. Finally, there was an issue about
epatotoxicity. Transaminase elevations of more than 3-fold
ccurred in more patients on lumiracoxib than in those on
Controlled Trials
Randomized Controlled Trials
Duration CV Outcome Results
12 h
xib
.
Treatment for
14 days;
follow-up
for 30 days
MI
Heart failure
Nonsignificant1 incidence
with parecoxib/
valdecoxib
No difference between the
2 groups
Cerebrovascular
event
Nonsignificant1 incidence
with parecoxib/
valdecoxib
nce,
h
xib
. IV
y
O
to
BG)
Treatment for
10 days;
follow-up
for 30 days
Composite of CV
death, MI,
ischemic
stroke, TIA,
DVT, and
pulmonary
embolism
1 Risk with parecoxib 
valdecoxib combination
compared with placebo:
HR 3.7 (1.0–13.5)
Trend toward1 risk with
placebo  valdecoxib
combination compared
with placebo: HR 2.0
(0.5–8.1)
(oral); q12 h  every 12 hours; TIA  transient ischemic attack; other abbreviations as in Tablesized
rom
tion
g IV q
aldeco
2 h vs
o
g IV o
IV q12
aldeco
2 h vs
wed b
0 mg P
PO
given
ost-CAhe 2 nonselective NSAIDs (hazard ratio [HR] 3.97, 95%
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Coxibs and Heart Disease January 2/9, 2007:1–14I 2.96 to 5.32). Whether or not this was a dose-dependent
henomenon related to supratherapeutic doses of lumira-
oxib remains unanswered. Nonetheless, on the basis of the
bove findings, it is difficult to justify the use of lumiracoxib
t this time (53). For patients not taking aspirin, the
bsolute reduction of 0.72% in ulcer complications is offset
y an excess of 2.0% of liver function test abnormalities and
ardiovascular Safety Data for Etoricoxib and Lumiracoxib From Ra
Table 5 Cardiovascular Safety Data for Etoricoxib and Lumiraco
Trial
Number
of Patients
Patient
Characteristics Intervention
Pooled analysis
of etoricoxib
phase IIB/III
trials (54)
6,700 RA, OA, chronic low
back pain
Etoricoxib vs. placebo
Etoricoxib vs. non-
naproxen NSAID
Etoricoxib vs. naprox
EDGE (54) 7,111 OA Etoricoxib 90 mg/da
vs. diclofenac
150 mg/day
EDGE II (54) 4,090 RA Etoricoxib 90 mg/da
vs. diclofenac
150 mg/day
MEDAL (54) 23,450 RA, OA Etoricoxib
OA: 60 mg/day
RA: 90 mg/day
vs. diclofenac
150 mg/day
TARGET (52) 18,325 OA Lumiracoxib 400 mg/
day vs. naproxen 50
mg 2x/day vs.
ibuprofen 800 mg
3x/day
(ASA allowed)
P  blood pressure; OR  odds ratio (numbers in parentheses represent the 95% interval); othen excess of 0.17% of MI if naproxen is used as the aomparator NSAID. For patients taking low-dose aspirin, it
s even harder to justify lumiracoxib because the benefit of
lcer complication reduction is lost.
Etoricoxib and lumiracoxib are the 2 newest coxibs that
ave yet to be examined for approval by the FDA. Clinical
rials of etoricoxib are ongoing and include EDGE II
Etoricoxib vs. Diclofenac Sodium Gastrointestinal Toler-
ized Controlled Trials
rom Randomized Controlled Trials
Duration CV Outcome Results
3 months Thrombotic CV events RR with etoricoxib 1.11
(0.32–3.81)
36 months Thrombotic CV events RR with etoricoxib 0.83
(0.26–2.64)
30 months Thrombotic CV events Trend toward1 risk with
etoricoxib: RR 1.70
(0.9–3.18)
Mean of 9 months
(maximum of 16
months)
Thrombotic CV events No difference between the
two groups: RR 1.01
(0.65–1.58)
APTC end point No difference between the
two groups: RR 0.99
(0.58–1.67)
Mean of 19 months
(maximum of 34
months)
Thrombotic CV events
(predefined)
Trials are ongoing
Mean of 20 months
(maximum of 40
months)
1 yr APTC end point
(predefined)
No difference among the
three groups
Lumiracoxib vs. nonselective
NSAIDs: HR 1.14
(0.78–1.66)
Lumiracoxib vs. naproxen:
HR 1.46 (0.89–2.37)
Lumiracoxib vs. ibuprofen:
HR 0.76 (0.41–1.40)
MI Trend toward1 risk with
lumiracoxib compared
with naproxen
Lumiracoxib vs. nonselective
NSAIDs: HR 1.31
(0.70–2.45)
Lumiracoxib vs. naproxen:
HR 1.77 (0.82–3.84)
Lumiracoxib vs. ibuprofen:
HR 0.66 (0.21–2.09)
Heart failure Less frequent in lumiracoxib
group than nonselective
NSAID group: OR 0.71
(0.39–1.3)
Systolic and diastolic
BP elevation
Less degree of elevation
with lumiracoxib
compared with
nonselective NSAIDs
viations as in Tables 1 and 2.ndom
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January 2/9, 2007:1–14 Coxibs and Heart Diseaseatients), which included 4,000 patients with RA, and
EDAL (Multinational Etoricoxib and Diclofenac Arthri-
is Long-term Study), which included 23,500 patients with
A and OA. The data from these 2 studies will be
ombined with those from the recently completed EDGE
rial, another trial of etoricoxib involving 7,111 patients, and
n analysis of predefined cardiovascular outcomes will be
ade. Together, the data from these trials will form the
argest NSAID analysis ever designed (54) (Table 5).
ther Potential Adverse
ardiovascular Effects of Coxibs
lthough nonselective NSAIDs have been associated with an
ncreased risk of congestive heart failure (CHF) or worsening
HF (55,56), it is less clear whether COX2 inhibitors share
he same risk. At least 2 observational studies have suggested
hat this risk is associated with rofecoxib but less so with
elecoxib (57,58). One of them was a population-based cohort
tudy that compared the rates of hospitalization for CHF
mong NSAID-naive elderly individuals who were started
n rofecoxib (n  14,583), celecoxib (n  18,908), and
onselective NSAIDs (n  5,391), and a randomly selected
ontrol group of non-NSAID users (n  100,000). Com-
ared with control patients and after adjustment for poten-
ial confounders, the relative risk (RR) of admission for
HF was significantly higher in those who received rofe-
oxib (RR 1.8, 95% CI 1.5 to 2.2) and nonselective
SAIDs (RR 1.4, 95% CI 1.0 to 1.9), but not in those
ho received celecoxib (RR 1.0, 95% CI 0.8 to 1.3). In
he APPROVe study, CHF and pulmonary edema occurred
arlier (about 5 months after starting the study drug) and at
higher rate in patients who took rofecoxib than in the
ontrol group (HR 4.61, 95% CI 1.50 to 18.83) (8).
Non-steroid anti-inflammatory drugs have also been
ssociated with blood pressure elevation and lower extremity
dema (59). Coxibs may share these risks, although once
gain, the greatest risk seems to be with rofecoxib. In a
eta-analysis of 19 randomized trials involving 45,461
atients, the weighted mean difference in systolic blood
ressure was 3.85/1.06 mm Hg and 2.83/1.34 mm
g when coxibs were compared with placebo and nonse-
ective NSAIDs, respectively (60). Among the different
oxibs that were compared with placebo, the largest increase
n systolic blood pressure was with rofecoxib (5.66 mm
g vs. 2.60 mm Hg with celecoxib). Rofecoxib also
esulted in a statistically significant increase in the risk of
ypertension compared with placebo (RR 2.63, 95% CI
.42 to 4.85), whereas celecoxib (RR 0.81, 95% CI 0.13 to
.21) and etoricoxib (RR 1.23, 95% CI 0.44 to 3.44) did
ot. Data from the CLASS and APPROVe trials suggested
imilar findings. In the CLASS trial, the incidence of
ypertension was lower in the celecoxib group compared
ith the nonselective NSAID group (1.7% vs. 2.3%, p
0.05), whereas the incidence of peripheral edema was
omparable between the 2 groups (2). The APPROVe ttudy, on the other hand, suggested an increased risk of
ypertension and peripheral edema with rofecoxib com-
ared with nonselective NSAIDs (8). Like celecoxib in the
LASS trial, lumiracoxib was not implicated in blood
ressure elevation in the TARGET trial; in fact, nonselec-
ive NSAIDs were associated with significantly higher mean
hanges in systolic and diastolic blood pressure compared
ith lumiracoxib (systolic blood pressure: 2.1 mm Hg
s. 0.4 mm Hg, p  0.0001; diastolic blood pressure:
0.5 mm Hg vs. 0.1 mm Hg, p  0.0001) (52).
onclusions
rawing conclusions from the numerous studies on coxibs
nd their cardiovascular risk obviously has not been straight-
orward. Although it is understandable why clinical trials on
rthritis patients would use nonselective NSAIDs as com-
arators, the lack of a placebo arm complicates the inter-
retation of the results, especially because NSAIDs may
ave cardiovascular effects themselves. In addition, most of
he data we have on coxibs were derived from post hoc and
on-prespecified analyses of randomized trials. We are still
n need of randomized controlled trials that are purposely
esigned and adequately powered to examine the cardiovascu-
ar effects of these drugs. One such trial has been planned for
elecoxib, PRECISION (Prospective Randomized Evaluation
f Celecoxib Integrated Safety vs. Ibuprofen or Naproxen),
hich hopes to assess the relative safety of these drugs in
bout 21,000 patients with OA or RA and known CAD or
ultiple risk factors for CAD over a duration of 2 years
61).
Amidst the multitude of studies on coxibs, one thing we
ave learned is what specific questions to ask. Although the
urrent data have their limitations, fortunately it is possible
o draw a fair number of conclusions to answer some of
hese questions.
First, are all coxibs the same? We do not believe so.
lthough there are good data from randomized trials of
ofecoxib, valdecoxib/parecoxib, and celecoxib to suggest
hat each of these drugs can result in adverse cardiovascular
vents (as though to suggest a class effect), there are likewise
umerous studies that indicate different degrees of risk
ssociated with different coxibs. The latter has been under-
cored by studies such as CLASS, PreSAP, ADAPT, and
UCCESS-1, which have shown no increased risk with
elecoxib, and observational studies that have shown differ-
nces in risks between rofecoxib and celecoxib. That these
ifferences are related to the COX2 selectivity of the drug or
ertain moieties within its chemical structure has been
uggested but cannot fully account for the findings of the
andomized trials. For example, of the various coxibs,
umiracoxib is the most COX2 selective, followed by rofe-
oxib and then celecoxib. The associated cardiovascular risks
een in the TARGET (lumiracoxib), VIGOR and
PPROVe (rofecoxib), and CLASS and APC (celecoxib)rials, however, did not line up in quite the same order.
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Coxibs and Heart Disease January 2/9, 2007:1–14nfortunately, there are no clinical trials that have made
ead-to-head comparisons of the various coxibs on which
e can substantiate this idea of a differential risk. It is also
mportant to point out that as much as we have scrutinized
he different coxibs, similar emphasis should be placed on
he impact of different doses on outcomes. The APC trial
howed quite clearly that the adverse events associated with
elecoxib were dose-dependent. In this light, concerns about
he safety of lumiracoxib in the TARGET trial, and most
ther coxibs for that matter, may be attenuated if lower
oses are used.
Second, how should the cardiovascular risk profile of a
atient affect our decision to use or not use a coxib?
hen the absolute risk increase in cardiovascular events
s expected to be high with coxib use, as in a patient with
AD or multiple risk factors for CAD, it is but prudent
o avoid a coxib. For the young, low-risk individual, the
cenario is less clear. The absolute risk increase in events
ay be lower, but the relative risk increase can potentially
e greater and still reach magnitudes of unacceptability.
his is a specific issue that needs clarification by well-
esigned studies.
Third, is it beneficial to add aspirin when prescribing a
oxib to a patient with an intermediate or high cardio-
ascular risk profile? Although the intuitive answer is yes,
nce again, the clinical trials do not provide us with a
traightforward answer. The post hoc analysis of the
PC data showed that patients who took aspirin did not
ave lower rates of cardiovascular events than those who
id not take aspirin. Similarly, in the APPROVe trial,
he increased cardiovascular risk experienced by the
ofecoxib group did not seem to be influenced by baseline
r subsequent use of aspirin. Findings such as these
uggest that the adverse outcomes from coxib use might
ot be solely a consequence of COX2 inhibition (or a
hromboxane-prostacyclin imbalance), and other mecha-
isms might be at play. What is perhaps clearer is the
nding that when aspirin is taken together with a coxib,
he gastrointestinal safety advantage of the coxib over a
onselective NSAID is lost. This was seen at least in the
LASS and TARGET trials.
Finally, is there still a place for coxibs in our scheme of
anaging patients with pain syndromes? Are there safer
ut equally efficacious alternatives? We believe that
oxibs will continue to be clinically useful, although in a
ery select group of patients. These are the individuals
ho continue to require nonsteroidal anti-inflammatory
reatment despite optimization of other modalities (e.g.,
isease-modifying drugs for RA and analgesics, physical
herapy, and physical aids for OA), have a low cardio-
ascular risk profile, and have a relatively high gastroin-
estinal bleeding risk. Although the vast majority of trials
hat compared nonselective NSAIDs with coxibs for pain
ontrol did not show superiority of the latter, in clinical
ractice, the response to pain management varies fromndividual to individual, and it is not uncommon to have
patient who reports better pain relief with a coxib.
Currently, the impetus for avoiding coxibs is the
otential to cause cardiovascular harm. Three important
oints arise from this statement. First, we actually lack
efinitive data about where the various nonselective
SAIDs, the presumed alternatives to coxibs, stand in
erms of cardiovascular safety. This is because there has
een no long-term placebo-controlled trial of conven-
ional NSAIDs designed to evaluate cardiovascular out-
omes. The vast majority of observational studies, how-
ver, have not shown any significant cardiovascular
onsequence from nonselective NSAID use, with the
xception of naproxen, which has been implicated to be
ildly cardioprotective by a few studies. A recent meta-
nalysis of placebo-controlled randomized trials also
ailed to show any significant cardiovascular effect of
onselective NSAIDs, including nabumetone, ibuprofen,
ndomethacin, diclofenac, and even naproxen, except
ossibly in trials of Alzheimer’s disease, in which there
as a nonsignificant trend toward increased events (62).
econd, certain NSAIDs, such as ibuprofen, can blunt
he antiplatelet effect of aspirin, presumably by binding to
OX1 and blocking the channel that aspirin must
raverse to bind COX1 (63). In view of this, it has been
ecommended that if aspirin and an NSAID are to be
aken on a regular basis, the soluble form of aspirin
hould be ingested 2 hours before the NSAID (64). This
ype of interaction becomes essentially irrelevant when
spirin is combined with a coxib because COX2 is not
xpressed in mature platelets. Finally, if a decision is
ade to avoid a coxib, the combination of an NSAID
ith a proton pump inhibitor (PPI) may be just as safe
or the upper gastrointestinal tract (65), but perhaps not
o for the lower gastrointestinal tract, in which a PPI is
ot expected to provide any protection (67). A clear
dvantage of using a nonselective NSAID/PPI combina-
ion is its lower cost compared with a coxib, especially if
ver-the-counter equivalents (e.g., naproxen or ibuprofen
lus omeprazole) are used. In patients with high cardio-
ascular risk who need to be on aspirin, more complex
olypharmacy-type combinations such as coxib/aspirin/
PI and nonselective NSAID/aspirin/PPI have been
uggested but have not been compared directly (66).
eprint requests and correspondence: Dr. Ernst R. Schwarz,
ivision of Cardiology, Cedars Sinai Medical Center, 8700
everly Boulevard, Suite 6215, Los Angeles, California 90048.
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